• OPEN AN ACCOUNT
Indian Indices
Sensex
76,515.43 362.57
( 0.48%)
Global Indices
Nasdaq
53,423.66 -283.45
(-0.53%)
Dow Jones
7,737.34 -31.37
(-0.40%)
Hang Seng
65,002.68 788.20
(1.23%)
Nikkei 225
10,828.70 -2.82
(-0.03%)
Forex
USD-INR
94.48 -0.24
(-0.26%)
EUR-INR
109.71 0.00
(0.00%)
GBP-INR
127.63 -0.19
(-0.15%)
JPY-INR
0.60 0.01
(1.60%)

EQUITY - MARKET SCREENER

Bal Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524824
INE083D01012
65.3864135
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BALPHARMA
18.56
140.98
EPS(TTM)
Face Value()
Div & Yield %
4.77
10
1.36
 

Marsons bags Rs 33-cr supply order from Vikran Engineering
Jun 10,2026
The order comprises various quantities of 17.6 MVA, 8.8 MVA and 4.4 MVA oil-cooled (ONAN), OCTC, outdoor-type, aluminum-wound inverter-duty transformers. The domestic order is scheduled to be executed within six months.

Marsons clarified that neither the promoter/promoter group nor group companies have any interest in the awarding entity, and the contract does not fall under related-party transactions.

Marsons is engaged in the business of manufacturing, trading & servicing transformers, transformer goods & other rental income. The company’s consolidated net profit surged 151.6% to Rs 22.62 crore on a 66% increase in net sales to Rs 92.65 crore in Q4 FY26 over Q4 FY25.

Shares of Marsons shed 0.61% to Rs 123 on the BSE.